BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Recruiting

Phase 2

Atigotatug & Nivolumab vs. DurvalumabBMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Sponsor:

SCRI Development Innovations, LLC

Code:

NCT06773910

Conditions

Limited Stage Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BMS-986489

Durvalumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-23. This information was provided to ClinicalTrials.gov by SCRI Development Innovations, LLC on 2025-08-08.